SR
Insider
Sumant Ramachandra
DirectorSumant Ramachandra (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Lyell Immunopharma, Inc. (LYEL). Across 1 priced purchase filing, the average 21-session return was -17.4% from execution and -14.2% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 4 days.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-17.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-14.2%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
–
no filings in the window
Last traded
Mar 21 2025
Filed Mar 25 2025
Median ADV $2.9M across their filed names
Open performance→Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 24 months
Most traded names
LYELRecent filings
LYELPURCHASE
Lyell Immunopharma, Inc.
View filing →
–200,000 sh · price not plausible
Exec Mar 21 2025
Filed Mar 25 2025 · 5:30 PM ET